{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-068002","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2026-05-29T13:56:10+00:00","discovered_at":"2026-05-29T13:57:00.201243+00:00","generated_at":"2026-05-29T13:57:13.665470+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Replimune to resubmit RP1 BLA for advanced melanoma; FDA agrees to prioritize review","bullets":["Company will resubmit BLA in coming days after collaborative FDA dialogue aligns on path forward.","FDA will treat resubmission as urgent matter and prioritize review due to high unmet need.","Approximately 8,500 Americans with advanced melanoma die each year; half fail checkpoint inhibitor therapy.","BLA supported by IGNYTE trial data in patients who progressed on anti-PD-1 therapy.","CEO Sushil Patel expressed gratitude to FDA for commitment to supporting patients and innovation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068002","json":"https://secwatch.observer/filing/0001104659-26-068002.json","markdown":"https://secwatch.observer/filing/0001104659-26-068002.md","text":"https://secwatch.observer/filing/0001104659-26-068002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926068002/0001104659-26-068002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926068002/tm2615980d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T13:57:13.665470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001140361-26-023560","ticker":"NJR","company_name":"NEW JERSEY RESOURCES CORP","filed_at":"2026-06-01T20:03:21+00:00","headline":"NJNG files base rate case seeking $157.6M increase; offers 8.9% winter bill cut","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023560","json":"https://secwatch.observer/filing/0001140361-26-023560.json","markdown":"https://secwatch.observer/filing/0001140361-26-023560.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/0001140361-26-023560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/ef20075084_8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-025629","ticker":"CDT","company_name":"CDT Equity Inc.","filed_at":"2026-05-28T20:30:30+00:00","headline":"CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025629","json":"https://secwatch.observer/filing/0001493152-26-025629.json","markdown":"https://secwatch.observer/filing/0001493152-26-025629.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001437749-26-018670","ticker":"BCDA","company_name":"BioCardia, Inc.","filed_at":"2026-05-28T12:00:11+00:00","headline":"BioCardia Japan PMDA supports CardiAMP cell therapy submission for HFrEF; submission planned Q4 2026","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018670","json":"https://secwatch.observer/filing/0001437749-26-018670.json","markdown":"https://secwatch.observer/filing/0001437749-26-018670.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774926018670/0001437749-26-018670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774926018670/bcda20260528_8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-061545","ticker":"CHAR","company_name":"Charlton Aria Acquisition Corp","filed_at":"2026-05-27T20:41:44+00:00","headline":"Charlton Aria receives Nasdaq delinquency notice for untimely Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061545","json":"https://secwatch.observer/filing/0001213900-26-061545.json","markdown":"https://secwatch.observer/filing/0001213900-26-061545.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/0001213900-26-061545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/ea0292193-8k_charlton.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-240645","ticker":"JAGX","company_name":"Jaguar Health, Inc.","filed_at":"2026-05-27T13:10:06+00:00","headline":"Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-240645","json":"https://secwatch.observer/filing/0001193125-26-240645.json","markdown":"https://secwatch.observer/filing/0001193125-26-240645.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/0001193125-26-240645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/d129501d8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-025277","ticker":"VSTD","company_name":"Vestand Inc.","filed_at":"2026-05-26T21:18:59+00:00","headline":"Vestand receives Nasdaq delisting notice for late quarterly and annual filings","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025277","json":"https://secwatch.observer/filing/0001493152-26-025277.json","markdown":"https://secwatch.observer/filing/0001493152-26-025277.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/0001493152-26-025277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001145197-26-000132","ticker":"PODD","company_name":"INSULET CORP","filed_at":"2026-05-26T20:06:27+00:00","headline":"Insulet voluntary correction for ~7M Omnipod Pods due to cannula tear, up to $50M cost","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001145197-26-000132","json":"https://secwatch.observer/filing/0001145197-26-000132.json","markdown":"https://secwatch.observer/filing/0001145197-26-000132.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1145197/000114519726000132/0001145197-26-000132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1145197/000114519726000132/podd-20260526.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}